Area of research
Genetics · Cancer Research
Research interest
Research interests include BRCA gene mutations in cancer, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer, and DNA Repair Mechanisms.
Uterine serous carcinoma and germline genetic testing: patterns of referral, completion and pathogenic variant detection
VISTA-induced tumor suppression by a four amino acid intracellular motif
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Germline <i>CDH1</i> Variants and Lifetime Cancer Risk
Abstract B008: The polyclonal path towards malignant transformation in familial adenomatous polyposis
Abstract 3872: Multi-ancestral origins of colorectal lesionsMulti-ancestral origins of colorectal lesions
Abstract PO2-13-10: Predicting outcomes in locally advanced breast cancer through profiling post-neoadjuvant tissue-based minimal residual disease
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
The New NCI Precision Medicine Trials
Abstract 3497: The polyclonal path to malignant transformation in familial adenomatous polyposis
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
MITI minimum information guidelines for highly multiplexed tissue images
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer
A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.
Abstract PD10-12: Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
Hereditary diffuse gastric cancer: updated clinical practice guidelines
Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer.
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in <i>BRCA1</i> and <i>BRCA2</i> wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study
Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <i>BRCA1</i> and <i>BRCA2</i> mutations
Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
Preventive surgery after multiplex genetic panel testing (MGPT).
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing<i>BRCA1</i>and<i>BRCA2</i>mutations
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018